
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems Inc. demonstrated a significant increase in its employee count, totaling 1,333 at year-end 2025, reflecting a commitment to growth and expanding operational capacity. The company also experienced a notable rise in advertising expenses, which reached $114.9 million in 2025, indicating a strategic investment in marketing to drive sales and brand awareness. Furthermore, projections for the global high-frequency neurostimulation (HGNS) market suggest sustained double-digit sales growth, with Inspire poised to benefit from an estimated 11% and 16% year-over-year growth in 2027 and 2028, respectively, promising a robust financial outlook.
Bears say
Inspire Medical Systems Inc has lowered its revenue guidance for FY 2026 from an anticipated range of $1,003-$1,013 million to $950-$1,000 million, reflecting concerns about reimbursement uncertainties and a decelerating domestic growth trajectory. The company faces additional headwinds due to confusion surrounding new coding for its reimbursement and potential disincentives for ENT surgeons to perform procedures involving its Inspire system. Given these challenges, coupled with a rocky initial rollout of the WISeR program and potential impacts on case approvals, a lower valuation multiple seems warranted as investors may perceive these issues as persistent overhangs on future growth.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares